Login to Your Account



Financings Roundup

Finding Gems in Junk, RaNA Emerges with $21M Series A

By Catherine Shaffer
BioWorld Today Contributing Writer

Thursday, January 19, 2012

Once thought to be useless junk of the genome, long noncoding RNA is getting some serious attention as a source of druggable targets. And that interest helped RaNA Therapeutics Inc., of Cambridge, Mass., land a $20.7 million Series A financing round led by Atlas Venture, SR One and Monsanto Co. – with participation by Partners Innovation Fund – to get its lncRNA discovery platform off the ground.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription